Therapeutic vaccines for advanced non-small cell lung cancer
Marcela Cortés-Jofré,Mikel Rueda-Etxebarria,Emeline Orillard,Elena Jimenez Tejero,José-Ramón Rueda
DOI: https://doi.org/10.1002/14651858.cd013377.pub2
IF: 8.4
2024-03-13
Cochrane Database of Systematic Reviews
Abstract:New strategies in immunotherapy with specific antigens that trigger an anti‐tumour immune response in people with lung cancer open the possibility of developing therapeutic vaccines aimed at boosting the adaptive immune response against cancer cells. To evaluate the effectiveness and safety of different types of therapeutic vaccines for people with advanced non‐small cell lung cancer. We searched CENTRAL, MEDLINE, Embase, Wanfang Data, and China Journal Net (CNKI) up to 22 August 2023. We included parallel‐group, randomised controlled trials evaluating a therapeutic cancer vaccine, alone or in combination with other treatments, in adults (> 18 years) with advanced non‐small cell lung cancer (NSCLC), whatever the line of treatment. We used standard methodological procedures expected by Cochrane. Our primary outcomes were overall survival, progression‐free survival, and serious adverse events; secondary outcomes were three‐ and five‐year survival rates and health‐related quality of life. We included 10 studies with 2177 participants. The outcome analyses included only 2045 participants (1401 men and 644 women). The certainty of the evidence varied by vaccine and outcome, and ranged from moderate to very low. We report only the results for primary outcomes here. TG4010 The addition of the vector‐based vaccine, TG4010, to chemotherapy, compared with chemotherapy alone in first‐line treatment, may result in little to no difference in overall survival (hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.65 to 1.05; 2 studies, 370 participants; low‐certainty evidence). It may increase progression‐free survival slightly (HR 0.74, 95% CI 0.55 to 0.99; 1 study, 222 participants; low‐certainty evidence). It may result in little to no difference in the proportion of participants with at least one serious treatment‐related adverse event, but the evidence is very uncertain (risk ratio (RR) 0.70, 95% CI 0.23 to 2.19; 2 studies, 362 participants; very low‐certainty evidence). Epidermal growth factor vaccine Epidermal growth factor vaccine, compared to best supportive care as switch maintenance treatment after first‐line chemotherapy, may result in little to no difference in overall survival (HR 0.82, 95% CI 0.66 to 1.02; 1 study, 378 participants; low‐certainty evidence), and in the proportion of participants with at least one serious treatment‐related adverse event (RR 1.32, 95% CI 0.88 to 1.98; 2 studies, 458 participants; low‐certainty evidence). hTERT (vx‐001) The hTERT (vx‐001) vaccine compared to placebo as maintenance treatment after first‐line chemotherapy may result in little to no difference in overall survival (HR 0.97, 95% CI 0.70 to 1.34; 1 study, 190 participants). Racotumomab Racotumomab compared to placebo as a switch maintenance treatment post‐chemotherapy was assessed in one study with 176 participants. It may increase overall survival (HR 0.63, 95% CI 0.46 to 0.87). It may make little to no difference in progression‐free survival (HR 0.73, 95% CI 0.53 to 1.00) and in the proportion of people with at least one serious treatment‐related adverse event (RR 1.03, 95% CI 0.15 to 7.18). Racotumomab versus docetaxel as switch maintenance therapy post‐chemotherapy was assessed in one study with 145 participants. The study did not report hazard rates on overall survival or progression‐free survival time, but the difference in median survival times was very small – less than one month. Racotumomab may result in little to no difference in the proportion of people with at least one serious treatment‐related adverse event compared with docetaxel (RR 0.89, 95% CI 0.44 to 1.83). Personalised peptide vaccine Personalised peptide vaccine plus docetaxel compared to docetaxel plus placebo post‐chemotherapy treatment may result in little to no difference in overall survival (HR 0.80, 95% CI 0.42 to 1.52) and progression‐free survival (HR 0.78, 95% CI 0.43 to 1.42). OSE2101 The OSE2101 vaccine compared with chemotherapy, after chemotherapy or immunotherapy, was assessed in one study with 219 participants. It may result in little to no difference in overall survival (HR 0.86, 95% CI 0.62 to 1.19). It may result in a small difference in the proportion of people with at least one serious treatment‐related adverse event (RR 0.95, 95% CI 0.91 to 0.99). SRL172 The SRL172 vaccine of killed Mycobacterium vaccae , added to chemotherapy, compared to chemotherapy alone, may result in no difference in overall survival, and may increase the proportion of people with at least one serious treatment‐related adverse event (RR 2.07, 95% CI 1.76 to 2.43; 351 participants). Adding a vaccine resulted in no differences in overall survival, except for racotumomab, which showed some improvement compared to placebo, but the difference in median survival time was very small (1.4 months) and the study only included 176 par -Abstract Truncated-
medicine, general & internal